Global Irritable Bowel Syndrome Treatment Market by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others), Medical Condition (IBS-constipation and IBS-diarrhea), Distribution Channel (Hospital Pharmacies, Online Pharmacies,

Global Irritable Bowel Syndrome Treatment Market by Drug Type (Lubiprostone, Linaclotide, Eluxadoline, Rifaximin, Alosetron, and others), Medical Condition (IBS-constipation and IBS-diarrhea), Distribution Channel (Hospital Pharmacies, Online Pharmacies, and Retail Pharmacies) and Region - Insights, Size, Share, Opportunity Analysis, and Industry Forecast, 2022 - 2028

The treatment of irritable bowel syndrome majorly revolves around relieving the patient from the symptoms associated with the condition, as the causes behind occurrence of irritable bowel syndrome are yet to be established. Patients suffering from irritable bowel syndrome show symptoms such as abdominal pain, diarrhea, and constipation. Long-term and recurring presence of these symptoms signals the possibility of irritable bowel syndrome. The treatment depends on severity of these symptoms, which are distinguished as mild, moderate, and severe. Mild symptoms do not significantly affect the quality of life. However, severe symptoms are more frequent and intense and need to be addressed. The disease is often linked with dietary, lifestyle factors, and stress, which can be controlled by managing stress levels, diet, and exercise. Severe symptoms need to be treated through medication prescribed by physicians. Two major therapy options are available for the treatment of IBS, namely, medical or drug therapy and nutritional therapy. Medical therapy includes drugs for relieving the symptoms and nutritional therapy by using fibers and probiotics or prebiotics depending on the situation.
Market Dynamics
The rise in number of gastrointestinal disorders are leading to increasing prevalence of irritable bowel syndrome, for which various companies such as Ironwood Pharmaceuticals, Inc. as well as NGOs conduct mass workshops for educating the people to incorporate healthy food habits as a major precaution towards prevention of IBS. Furthermore, major growth drivers for the irritable bowel syndrome treatment market are expected launches of various pipeline drugs for the treatment during the forecast period and increase in levels of stress associated with changing lifestyle as people suffering from IBS have a colon with sensitivity towards certain foods and stress. According to a survey by Buscopan IBS Relief in 2016, stress was the cause for seven out of ten patients suffering from gastrointestinal pain. The large population of stress and anxiety disorder patients are expected to fuel the growth of the global irritable bowel syndrome treatment market.
Market Taxonomy
This report segments the global irritable bowel syndrome treatment market on the basis of drug type, medical condition, and distribution channel. On the basis of drug type, the global irritable bowel syndrome treatment market is segmented into lubiprostone, linaclotide, eluxadoline, rifaximin, Ramosetron Hydrochloride and others. Medical conditions of irritable bowel syndrome includes IBS-constipation and IBS-diarrhea. Irritable bowel syndrome treatment market is segmented by distribution channel as hospital pharmacies, online pharmacies and retail pharmacies.
Key features of the study:
This report provides in-depth analysis of irritable bowel syndrome treatment market and provides market size (US$ Million) and Cumulative Annual Growth Rate (CAGR %) for the forecast period (2022-2028), considering 2021 as the base year
It elucidates potential revenue opportunity across different segments and explains attractive investment proposition matrix for this market
This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, regional outlook, and competitive strategy adopted by the leading players
It profiles leading players in the global irritable bowel syndrome treatment market based on the following parameters – company overview, financial performance, product portfolio, geographical presence, distribution strategies, key developments and strategies, and future plans
Key companies covered as a part of this study include Abbott Laboratories*, Synergy Pharmaceuticals, Inc., Sucampo Pharmaceuticals, Inc., Valeant Pharmaceuticals International, Inc., Ardelyx, Inc., Astellas Pharma Inc., Novartis AG, GlaxoSmithKline plc., Ironwood Pharmaceuticals, Inc.
Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launch, technology up-gradation, market expansion, and marketing tactics
The global irritable bowel syndrome treatment market report caters to various stakeholders in this industry including investors, suppliers, drug manufacturers, distributors, new entrants, and financial analysts
Stakeholders would have ease in decision making through the various strategy matrices used in analyzing the Irritable Bowel Syndrome Treatment Market
Detailed Segmentation:
Global Irritable Bowel Syndrome Treatment Market, By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
Global Irritable Bowel Syndrome Treatment Market, By Medical Condition:
IBS-Constipation
IBS-Diarrhea
Global Irritable Bowel Syndrome Treatment Market, By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
Global Irritable Bowel Syndrome Treatment Market, By Geography:
North America
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
U.S.
Canada
Europe
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
U.K.
Italy
Spain
Russia
Rest of Europe
Asia-Pacific
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
China
Japan
ASEAN
Rest of Asia Pacific
Latin America
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
Mexico
Rest of Latin America
Middle East
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
Israel
Rest of Middle East
Africa
By Drug Type:
Lubiprostone
Linaclotide
Eluxadoline
Rifaximin
Ramosetron Hydrochloride
Others
By Medical Condition:
IBS-Constipation
IBS-Diarrhea
By Distribution Channel:
Hospital Pharmacies
Online Pharmacies
Retail Pharmacies
By Country:
South Africa
Rest of Africa
Company Profiles
Abbott Laboratories *
Company Overview
Product Portfolio
Financial Performance
Key Strategies
Recent Developments
Future Plans
Synergy Pharmaceuticals, Inc.
Sucampo Pharmaceuticals, Inc.
Valeant Pharmaceuticals International, Inc.
Ardelyx, Inc.
Astellas Pharma Inc.
Novartis AG
GlaxoSmithKline plc.
Ironwood Pharmaceuticals, Inc.
“*” marked represents similar segmentation in other categories in the respective section.